Cowpea Mosaic Virus (CPMV)-Based Cancer Testis Antigen NY-ESO-1 Vaccine Elicits an Antigen-Specific Cytotoxic T Cell Response.
Bindi K PatelChao WangBraulio LorensAlan D LevineNicole F SteinmetzSourabh ShuklaPublished in: ACS applied bio materials (2020)
Cancer vaccines are promising adjuvant immunotherapies that can stimulate the immune system to recognize tumor-associated antigens and eliminate the residual or recurring disease. The aberrant and restricted expression of highly immunogenic cancer testis antigen NY-ESO-1 in several malignancies, including triple-negative breast cancer, melanoma, myelomas, and ovarian cancer, makes NY-ESO-1 an attractive antigenic target for cancer vaccines. This study describes a NY-ESO-1 vaccine based on a bio-inspired nanomaterial platform technology, specifically a plant virus nanoparticle. The 30 nm icosahedral plant virus cowpea mosaic virus (CPMV) displaying multiple copies of human HLA-A2 restricted peptide antigen NY-ESO-1157-165 exhibited enhanced uptake and activation of antigen-presenting cells and stimulated a potent CD8+ T cell response in transgenic human HLA-A2 expressing mice. CD8+ T cells from immunized mice exhibited antigen-specific proliferation and cancer cell cytotoxicity, highlighting the potential application of a CPMV-NY-ESO-1 vaccine against NY-ESO-1+ malignancies.
Keyphrases
- papillary thyroid
- endothelial cells
- poor prognosis
- lymph node metastasis
- metabolic syndrome
- adipose tissue
- early stage
- high throughput
- high fat diet induced
- induced apoptosis
- squamous cell carcinoma
- signaling pathway
- oxidative stress
- cell death
- dendritic cells
- photodynamic therapy
- induced pluripotent stem cells
- cell cycle arrest
- case report
- climate change
- binding protein